IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07198841 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (Non-Small Cell)

Interventions

DRUG: IBI351 combined with cetuximab β

Sponsor

Guangdong Association of Clinical Trials

Collaborators

[object Object]
[object Object]